On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation. The patent world is watching, particularly those who focus on emerging technologies. On March 14, 2013, the NanoBusiness Commercialization Association filed a brief in support of Myriad Genetics (brief prepared by Foley & Lardner, LLP). In addition to arguing that the patent claims should be patent eligible, which is the essence of the case, the brief also argues that patents do not preempt others from experimenting on, improving upon, or designing around a patented invention. With today being the first day of the new first-to-file regime, patent lawyers of all stripes are busy these days keeping up with dramatic changes to the patent system. The Supreme Court could use the Myriad case to establish a new paradigm for patent eligibility. Stay tuned.
相关见解
December 12, 2025
Health Care Law Today
Eleventh Circuit Hears Oral Argument in Landmark Constitutional Challenge to False Claims Act’s Qui Tam Provisions
On December 12, the U.S. Court of Appeals for the Eleventh Circuit heard oral argument in U.S. ex rel. Zafirov v. Florida Medical…
2025年12月11日
福莱观点
知识产权组合管理中的反垄断风险与合规策略
本文分析了知识产权组合管理如何在促进创新的同时,也可能带来潜在风险……
2025年12月11日
福莱观点
加州空气资源委员会发布SB 261和SB 253法案的拟议法规
2025年12月9日,加州空气资源委员会(CARB)发布了其针对初始法规的拟议监管文本……